Tretinoin: a review of the nonclinical developmental toxicology experience

Area of Science:

• Pharmacology
• Toxicology
• Dermatology

Background:

• Tretinoin's potential for embryofetal developmental toxicity requires thorough evaluation.
• Structurally similar retinoids, like isotretinoin, are known human and animal teratogens.
• Understanding the differences in toxicity between tretinoin and isotretinoin is crucial.

Purpose of the Study:

• To assess the developmental toxicity of topical tretinoin.
• To compare the teratogenic potential of topical versus oral tretinoin.
• To investigate the pharmacokinetic profile of topical tretinoin and its implications for fetal exposure.

Main Methods:

• Review of existing developmental toxicology studies on tretinoin and related compounds.
• Analysis of pharmacokinetic data regarding skin absorption and systemic exposure.
• Comparison of teratogenic doses and effects across different administration routes and animal models.

Main Results:

• Oral tretinoin causes developmental anomalies in animal models at doses of 2.5-10 mg/kg.
• Topical tretinoin application did not induce malformations in laboratory animals.
• Poor skin absorption of topical tretinoin results in maternal plasma concentrations below toxic levels.

Conclusions:

• Differences in metabolism and transplacental transfer explain varying retinoid toxicities.
• Pharmacokinetic data indicate negligible fetal exposure risk with therapeutic topical tretinoin use.
• The human risk of fetal anomalies from topical tretinoin is considered negligible.